THOMAS, MCNERNEY & PARTNERS EXPANDS TEAM ON EAST AND WEST COASTS
Eric Aguiar, M.D.
joins Connecticut office as Partner and Jason Brown, Ph.D. joins San
Francisco office as Associate
STAMFORD, CT & SAN FRANCISCO, CA– OCTOBER 17, 2007 -
Thomas, McNerney & Partners, LLC, a health care venture capital firm that
invests in life science and medical technology companies, today announced that
Eric Aguiar, M.D., has joined as a partner in the firm’s Connecticut office.
Since 2001, Dr. Aguiar has been a managing director in the Boston and Princeton
offices of HealthCare Ventures.
“Eric’s deep experience in venture capital and biopharmaceutical
operations complements our multi-faceted team and helps to further
expand our reach along the East Coast,” said James Thomas, partner. “His
investment expertise and operational experience will be an asset to the
firm as he builds upon our core strengths in identifying, financing and
building biopharmaceutical opportunities.”
Aguiar has more than 12 years of venture capital experience, most
recently as managing director of HealthCare Ventures. Prior to joining
HealthCare Ventures, he was chief executive officer of Genovo Inc., a
biopharmaceutical company specializing in gene delivery and gene
regulation. Prior to Genovo, Dr. Aguiar served as an executive director
at TheraTech, Inc., which was later acquired by Watson Pharmaceuticals.
For five years he was also managing director of Philadelphia Ventures
where he served on the board of several biotechnology companies. Dr.
Aguiar is also a member of the board of overseers of the Tufts School of
“Thomas, McNerney & Partners’ broad mandate to invest in companies at
all stages of development in a variety of health care sectors and its
history of success in leading its portfolio investments is what
attracted me to the firm,” said Dr. Aguiar. “I look forward to joining
the partnership and expanding the firm’s capabilities in the
addition to Dr. Aguiar, Jason Brown, Ph.D. joined the firm as an
associate in the San Francisco office.
Dr. Brown was most recently a member of the investment team at Forward
Ventures, where he played an active role in Forward-led rounds of
investment totaling more than $50 million. Prior to joining Forward, he
conducted research in antimicrobial drug discovery and bacterial
genomics as a postdoctoral fellow in Infectious Diseases at Johnson &
Johnson Pharmaceutical Research and Development. About Thomas,
McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with
approximately $600 million under management focused on investing in life
science and medical technology companies at all stages of development.
In addition to helping entrepreneurs launch companies with seed and
early stage funding, the firm provides growth capital to emerging
companies to advance clinical development or for product
commercialization. Thomas, McNerney & Partners also is involved in
spinning out products and divisions from major medical device and
pharmaceutical companies, consolidating companies through roll-up
strategies and participating in structured financings for public
companies as well as recapitalizations. The firm is targeting
investments in the pharmaceutical, medical device, biotechnology and
diagnostic sectors and in other areas utilizing medical technology
innovation. The firm has offices in Stamford , Minneapolis and San
Francisco . For further information, please visit